

|                                     |                                       | Trials Conducted to Date or in Progress |         |         |         | Marketed |
|-------------------------------------|---------------------------------------|---|---------|---------|---------|----------|
|                                     |                                       | Preclinical                             | Phase 1 | Phase 2 | Phase 3 |          |
| <b><i>PROPHYLACTIC VACCINES</i></b> |                                       |   |         |         |         |          |
| COVID-19                            |                                       | ▶                                       |         |         |         |          |
| Norovirus <sup>1</sup>              | Bivalent                              | ▶                                       |         |         |         |          |
| Seasonal Influenza <sup>2</sup>     | Monovalent                            | ▶                                       |         |         |         |          |
|                                     | Quadrivalent                          | ▶                                       |         |         |         |          |
| Influenza                           | Universal <sup>3</sup>                | ▶                                       |         |         |         |          |
| RSV <sup>4</sup>                    |                                       | ▶                                       |         |         |         |          |
| <b><i>THERAPEUTIC VACCINES</i></b>  |                                       |   |         |         |         |          |
| HPV <sup>5</sup>                    | HPV, cervical dysplasia and/or cancer | ▶                                       |         |         |         |          |



- 1) Bivalent Phase 1 demonstrated IgA ASC response rates of 90 – 93% for GII.4 and 78 – 86% for GI.1
- 2) Monovalent H1 flu vaccine completed phase 2 Proof of Concept efficacy study.
- 3) Janssen collaboration with an option to negotiate an exclusive license.
- 4) RSV program to be partnered with new antigen partner.
- 5) HPV therapeutic pre-IND feedback received.